Aelis Farma Management
Management criteria checks 3/4
Aelis Farma's CEO is Pier Piazza, appointed in Jan 2022, has a tenure of 2.25 years. total yearly compensation is €473.61K, comprised of 63.3% salary and 36.7% bonuses, including company stock and options. directly owns 15.86% of the company’s shares, worth €27.06M. The average tenure of the management team and the board of directors is 2.3 years and 2.3 years respectively.
Key information
Pier Piazza
Chief executive officer
€473.6k
Total compensation
| CEO salary percentage | 63.3% |
| CEO tenure | 2.3yrs |
| CEO ownership | 15.9% |
| Management average tenure | 2.3yrs |
| Board average tenure | 2.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | €474k | €300k | -€5m |
| Sep 30 2023 | n/a | n/a | -€5m |
| Jun 30 2023 | n/a | n/a | -€6m |
| Mar 31 2023 | n/a | n/a | -€10m |
| Dec 31 2022 | €594k | €296k | -€14m |
| Sep 30 2022 | n/a | n/a | -€14m |
| Jun 30 2022 | n/a | n/a | -€14m |
| Mar 31 2022 | n/a | n/a | -€6m |
| Dec 31 2021 | €501k | €239k | €574k |
| Sep 30 2021 | n/a | n/a | €2m |
| Jun 30 2021 | n/a | n/a | €3m |
| Mar 31 2021 | n/a | n/a | €504k |
| Dec 31 2020 | €347k | €210k | -€2m |
Compensation vs Market: Pier's total compensation ($USD506.65K) is about average for companies of similar size in the French market ($USD556.08K).
Compensation vs Earnings: Pier's compensation has been consistent with company performance over the past year.
CEO
Pier Piazza (62 yo)
2.3yrs
Tenure
€473,614
Compensation
Dr. Pier Vincenzo Piazza, MD, Ph D., is CEO of Aelis Farma S.A. from January 11, 2022 and serves as its Director since 2017. Dr. Piazza is an entrepreneur and renowned scientist who has been involved in es...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | €473.61k | 15.86% € 27.1m | |
| Head of Finance | 2.3yrs | no data | no data | |
| Chief Operating Officer | no data | no data | no data | |
| Head of Legal | 2.3yrs | no data | no data | |
| Chief Corporate Development Officer | less than a year | no data | no data | |
| Head of Discovery & IP Leader | 2.3yrs | no data | no data | |
| Head of Preclinical Development | 2.3yrs | no data | no data | |
| Head of Clinical Development | 2.3yrs | no data | no data | |
| Head of Pharmaceutical Development | 2.3yrs | no data | no data |
2.3yrs
Average Tenure
Experienced Management: AELIS's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.3yrs | €473.61k | 15.86% € 27.1m | |
| Censor | 2.3yrs | €30.00k | 12.22% € 20.9m | |
| Independent Chairman of the Board | 4.2yrs | €100.00k | no data | |
| Chairman of the Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.3yrs | no data | no data | |
| Independent Director | 2.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Director | 3.3yrs | no data | 8.95% € 15.3m | |
| Independent Director | 2.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.3yrs
Average Tenure
63yo
Average Age
Experienced Board: AELIS's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.